Skip to main content
Top
Published in: Infection 1/2013

01-02-2013 | Clinical and Epidemiological Study

MRSA decolonization: success rate, risk factors for failure and optimal duration of follow-up

Authors: P. Kohler, A. Bregenzer-Witteck, G. Rettenmund, S. Otterbech, M. Schlegel

Published in: Infection | Issue 1/2013

Login to get access

Abstract

Purpose

Methicillin-resistant Staphylococcus aureus (MRSA) decolonization is a widely established, though controversial part of many MRSA controlling strategies. The aim of this study was to evaluate our decolonization success rate, identify the risk factors for decolonization failure and determine the optimal duration of follow-up in our low MRSA prevalence setting (2.6 % of isolates).

Methods

Every patient with newly detected MRSA colonization or infection between January 2007 and December 2009 was recruited to the study. The MRSA strategy of our institution (a 700 bed tertiary hospital in eastern Switzerland) consists of a 5-day regimen of nasal mupirocin ointment, chlorhexidin mouth rinse and whole body wash with didecyldimonium chloride. Systemic antibiotics are usually not added to the regimen.

Results

We determined a MRSA decolonization success rate of 65 % (33/51) after a median follow-up of 13 months [i.e. a tripling of the spontaneous clearance rate of 22 % (6/27) in the non-decolonized group]. The most important risk factor for decolonization failure was colonization of the respiratory tract [odds risk (OR) 9.1, 95 % confidence interval (CI) 1.2–66.7], as well as isolation of MRSA spa-type 002 ([R 5.8, 95 % CI 1.0–33.3). Of all the episodes of MRSA recurrence, 88 % (14/16) were detected within 270 days after decolonization.

Conclusion

High MRSA decolonization success rates can be achieved without the routine use of oral antibiotics. A time period of 1 year after decolonization seems to be a reasonable duration of follow-up in our setting. We encourage other institutions to take into account local MRSA epidemiology (e.g. predominance of certain subtypes) for the management of MRSA patients.
Literature
1.
go back to reference Huang S, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003;36:281–5.PubMedCrossRef Huang S, Platt R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003;36:281–5.PubMedCrossRef
2.
go back to reference Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. 2001;48[Suppl A]:S9–14.PubMedCrossRef Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. 2001;48[Suppl A]:S9–14.PubMedCrossRef
3.
go back to reference Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev. 2003;(4):CD003340. Loeb M, Main C, Walker-Dilks C, Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev. 2003;(4):CD003340.
4.
go back to reference Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus? Clin Infect Dis. 2010;51(5):585–90.PubMedCrossRef Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible Staphylococcus aureus hold lessons for methicillin-resistant S. aureus? Clin Infect Dis. 2010;51(5):585–90.PubMedCrossRef
5.
go back to reference Robicsek A, Beaumont JL, Thomson RB Jr, Govindarajan G, Peterson LR. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol. 2009;30:623–32.PubMedCrossRef Robicsek A, Beaumont JL, Thomson RB Jr, Govindarajan G, Peterson LR. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol. 2009;30:623–32.PubMedCrossRef
6.
go back to reference Dow G, Field D, Mancuso M, Allard J. Decolonization of methicillin-resistant Staphylococcus aureus during routine hospital care: efficacy and long-term follow-up. Can J Infect Dis Med Microbiol. 2010;21(1):38–44.PubMed Dow G, Field D, Mancuso M, Allard J. Decolonization of methicillin-resistant Staphylococcus aureus during routine hospital care: efficacy and long-term follow-up. Can J Infect Dis Med Microbiol. 2010;21(1):38–44.PubMed
7.
go back to reference Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009;48:922–30.PubMedCrossRef Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis. 2009;48:922–30.PubMedCrossRef
8.
go back to reference Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008;29(6):510–6.PubMedCrossRef Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol. 2008;29(6):510–6.PubMedCrossRef
9.
go back to reference Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2000;31(6):1380–5.PubMedCrossRef Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2000;31(6):1380–5.PubMedCrossRef
10.
go back to reference Institut für Klinische Mikrobiologie und Immunologie (IKMI) Antibiotika-Empfindlichkeit der wichtigsten Gram-positiven Bakterien und Gram-negativen Non-Enterobacteriaceae. St. Gallen. 2007. Available at: www.ikmi.ch. Institut für Klinische Mikrobiologie und Immunologie (IKMI) Antibiotika-Empfindlichkeit der wichtigsten Gram-positiven Bakterien und Gram-negativen Non-Enterobacteriaceae. St. Gallen. 2007. Available at: www.​ikmi.​ch.
11.
go back to reference Verhoef J, Beaujean D, Blok H, Baars A, Meyler A, van der Werken C, Weersink A. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999;18(7):461–6.PubMedCrossRef Verhoef J, Beaujean D, Blok H, Baars A, Meyler A, van der Werken C, Weersink A. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1999;18(7):461–6.PubMedCrossRef
12.
go back to reference Witteck A, Rettenmund G, Schlegel M. MRSA admission screening in a low prevalence setting—much ado about nothing? Swiss Med Wkly. 2011;7(141):w13217. Witteck A, Rettenmund G, Schlegel M. MRSA admission screening in a low prevalence setting—much ado about nothing? Swiss Med Wkly. 2011;7(141):w13217.
13.
go back to reference Mathews AA, Thomas M, Appalaraju B, Jayalakshmi J. Evaluation and comparison of tests to detect methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2010;53(1):79–82.PubMedCrossRef Mathews AA, Thomas M, Appalaraju B, Jayalakshmi J. Evaluation and comparison of tests to detect methicillin-resistant Staphylococcus aureus. Indian J Pathol Microbiol. 2010;53(1):79–82.PubMedCrossRef
14.
go back to reference Brown DF, Edwards DI, Hawkey PM, et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother. 2005;56(6):1000–8.PubMedCrossRef Brown DF, Edwards DI, Hawkey PM, et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother. 2005;56(6):1000–8.PubMedCrossRef
15.
go back to reference Fleisch F, Oechslin EC, Gujer AR, Ritzler E, Imhof A, Ruef C, Reinhart WH. Transregional spread of a single clone of methicillin-resistant Staphylococcus aureus between groups of drug users in Switzerland. Infection. 2005;33(4):273–7.PubMedCrossRef Fleisch F, Oechslin EC, Gujer AR, Ritzler E, Imhof A, Ruef C, Reinhart WH. Transregional spread of a single clone of methicillin-resistant Staphylococcus aureus between groups of drug users in Switzerland. Infection. 2005;33(4):273–7.PubMedCrossRef
16.
go back to reference Fenner L, Widmer AF, Dangel M, Frei R. Distribution of spa types among meticillin-resistant Staphylococcus aureus isolates during a 6 year period at a low-prevalence University Hospital. J Med Microbiol. 2008;57(Pt 5):612–6.PubMedCrossRef Fenner L, Widmer AF, Dangel M, Frei R. Distribution of spa types among meticillin-resistant Staphylococcus aureus isolates during a 6 year period at a low-prevalence University Hospital. J Med Microbiol. 2008;57(Pt 5):612–6.PubMedCrossRef
17.
go back to reference Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother. 2011;66(10):2409–17.PubMedCrossRef Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline. J Antimicrob Chemother. 2011;66(10):2409–17.PubMedCrossRef
18.
go back to reference Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, European Staphylococcal Reference Laboratory Working Group. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med. 2010;7(1):e1000215.PubMedCrossRef Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, European Staphylococcal Reference Laboratory Working Group. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med. 2010;7(1):e1000215.PubMedCrossRef
19.
go back to reference Pan A, Lee A, Cooper B, Chalfine A, Daikos G, Garilli S, Malhotra-Kumar S, Martinez JA, Patroni A, Harbarth S, MOSAR-04 Study Team. Risk factors for previously unknown methicillin-resistant Staphylococcus aureus (MRSA) carriage on admission to 13 surgical wards in Europe. BMC Proc. 2011;5[Suppl 6]:O85.CrossRef Pan A, Lee A, Cooper B, Chalfine A, Daikos G, Garilli S, Malhotra-Kumar S, Martinez JA, Patroni A, Harbarth S, MOSAR-04 Study Team. Risk factors for previously unknown methicillin-resistant Staphylococcus aureus (MRSA) carriage on admission to 13 surgical wards in Europe. BMC Proc. 2011;5[Suppl 6]:O85.CrossRef
20.
go back to reference Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10(9):1627–34.PubMedCrossRef Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis. 2004;10(9):1627–34.PubMedCrossRef
21.
go back to reference Hudson LO, Murphy CR, Spratt BG, Enright MC, Terpstra L, Gombosev A, Hannah P, Mikhail L, Alexander R, Moore DF, Huang SS. Differences in methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from pediatric and adult patients from hospitals in a large California County. J Clin Microbiol. 2012;50(3):573–9. Hudson LO, Murphy CR, Spratt BG, Enright MC, Terpstra L, Gombosev A, Hannah P, Mikhail L, Alexander R, Moore DF, Huang SS. Differences in methicillin-resistant Staphylococcus aureus (MRSA) strains isolated from pediatric and adult patients from hospitals in a large California County. J Clin Microbiol. 2012;50(3):573–9.
22.
go back to reference Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Pérez-Vázquez M, Marín M, Spanish Group for the Study of Staphylococcus. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol. 2009;47(6):1620–7.PubMedCrossRef Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Pérez-Vázquez M, Marín M, Spanish Group for the Study of Staphylococcus. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol. 2009;47(6):1620–7.PubMedCrossRef
23.
go back to reference Larsson AK, Gustafsson E, Nilsson AC, Odenholt I, Ringberg H, Melander E. Duration of methicillin-resistant Staphylococcus aureus colonization after diagnosis: a four-year experience from southern Sweden. Scand J Infect Dis. 2011;43(6–7):456–62.PubMedCrossRef Larsson AK, Gustafsson E, Nilsson AC, Odenholt I, Ringberg H, Melander E. Duration of methicillin-resistant Staphylococcus aureus colonization after diagnosis: a four-year experience from southern Sweden. Scand J Infect Dis. 2011;43(6–7):456–62.PubMedCrossRef
24.
go back to reference Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure. J Antimicrob Chemother. 2011;66(10):2418–24.PubMedCrossRef Ammerlaan HS, Kluytmans JA, Berkhout H, Buiting A, de Brauwer EI, van den Broek PJ, van Gelderen P, Leenders SA, Ott A, Richter C, Spanjaard L, Spijkerman IJ, van Tiel FH, Voorn GP, Wulf MW, van Zeijl J, Troelstra A, MRSA Eradication Study Group. Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure. J Antimicrob Chemother. 2011;66(10):2418–24.PubMedCrossRef
25.
go back to reference Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178–85.PubMedCrossRef Simor AE, Phillips E, McGeer A, Konvalinka A, Loeb M, Devlin HR, Kiss A. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis. 2007;44(2):178–85.PubMedCrossRef
26.
go back to reference Marschall J, Muehlemann K. Duration of MRSA-carriage, according to risk factors for acquisition. Infect Control Hosp Epidemiol. 2006;27(11):1206–12.PubMedCrossRef Marschall J, Muehlemann K. Duration of MRSA-carriage, according to risk factors for acquisition. Infect Control Hosp Epidemiol. 2006;27(11):1206–12.PubMedCrossRef
Metadata
Title
MRSA decolonization: success rate, risk factors for failure and optimal duration of follow-up
Authors
P. Kohler
A. Bregenzer-Witteck
G. Rettenmund
S. Otterbech
M. Schlegel
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Infection / Issue 1/2013
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0290-1

Other articles of this Issue 1/2013

Infection 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine